|
1
|
Ilic N, Petricevic A, Arar D, Kotarac S,
Banovic J, Ilic NF, Tripkovic A and Grandic L: Skip mediastinal
nodal metastases in the IIIa/N2 non-small cell lung cancer. J
Thorac Oncol. 2:1018–1021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ni T, Mao G, Xue Q, Liu Y, Chen B, Cui X,
Lv L, Jia L, Wang Y and Ji L: Upregulated expression of ILF2 in
non-small cell lung cancer is associated with tumor cell
proliferation and poor prognosis. J Mol Histol. 46:325–335. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu
L, Yin Y and Shu Y: Gefitinib or erlotinib as maintenance therapy
in patients with advanced stage non-small cell lung cancer: A
systematic review. PLoS One. 8:e593142013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, Zhou J, Zhang Y, Wang Y, Cheng L,
Bai Y and Ma H: The value of microRNA-155 as a prognostic factor
for survival in non-small cell lung cancer: A meta-analysis. PLoS
One. 10:e01368892015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I: EUROCARE-4 Working
Group: Recent cancer survival in Europe: A 2000-02 period analysis
of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakashita S, Sakashita M and Tsao M Sound:
Genes and pathology of non-small cell lung carcinoma. Semin Oncol.
41:28–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei J, Ma Z, Li Y, Zhao B, Wang D and Jin
Y and Jin Y: miR-143 inhibits cell proliferation by targeting
autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol
Med Rep. 11:571–576. 2015.PubMed/NCBI
|
|
10
|
Wu D, Pan H, Zhou Y, Zhang Z, Qu P, Zhou J
and Wang W: Upregulation of microRNA-204 inhibits cell
proliferation, migration and invasion in human renal cell carcinoma
cells by downregulating SOX4. Mol Med Rep. 12:7059–7064.
2015.PubMed/NCBI
|
|
11
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
12
|
Ebrahimi A and Sadroddiny E: MicroRNAs in
lung diseases: Recent findings and their pathophysiological
implications. Pulm Pharmacol Ther. 34:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Abdel-Mageed AB, Mondal D and Kandil
E: MicroRNA expression profiles in differentiated thyroid cancer, a
review. Int J Clin Exp Med. 6:74–80. 2013.PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Gao P, Lin F, Long M, Weng Y,
Ouyang Y, Liu L, Wei J, Chen X, He T, et al: Wilms' tumour
suppressor gene 1 (WT1) is involved in the carcinogenesis of lung
cancer through interaction with PI3K/Akt pathway. Cancer Cell Int.
13:1142013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang
Y, Ye S, Wu S, Zhong G, Ren J, et al: MicroRNA-143 inhibits
migration and invasion of human non-small-cell lung cancer and its
relative mechanism. Int J Biol Sci. 9:680–692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Yang X, Wu H, Zhou W and Liu Z:
MicroRNA-145 inhibits migration and invasion via inhibition of
fascin 1 protein expression in non-small-cell lung cancer cells.
Mol Med Rep. 12:6193–6198. 2015.PubMed/NCBI
|
|
23
|
Kanitz A, Imig J, Dziunycz PJ, Primorac A,
Galgano A, Hofbauer GF, Gerber AP and Detmar M: The expression
levels of microRNA-361-5p and its target VEGFA are inversely
correlated in human cutaneous squamous cell carcinoma. PLoS One.
7:e495682012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin
C, Wu Y, Guan G, Sha R, Zhou Q, et al: MiR-361-5p inhibits
colorectal and gastric cancer growth and metastasis by targeting
staphylococcal nuclease domain containing-1. Oncotarget.
6:17404–17416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu D, Tao T, Xu B, Chen S, Liu C, Zhang
L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a
tumor suppressor in prostate cancer by targeting signal transducer
and activator of transcription-6 (STAT6). Biochem Biophys Res
Commun. 445:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu X, Xi X, Yan Q, Zhang Z, Cai B, Lu W
and Wan X: MicroRNA-361-5p facilitates cervical cancer progression
through mediation of epithelial-to-mesenchymal transition. Med
Oncol. 30:7512013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Call KM, Glaser T, Ito CY, Buckler AJ,
Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al:
Isolation and characterization of a zinc finger polypeptide gene at
the human chromosome 11 Wilms' tumor locus. Cell. 60:509–520. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gessler M, Poustka A, Cavenee W, Neve RL,
Orkin SH and Bruns GA: Homozygous deletion in Wilms tumours of a
zinc-finger gene identified by chromosome jumping. Nature.
343:774–778. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hohenstein P and Hastie ND: The many
facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 15:R196–R201.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A,
Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, et al: Expression
of the Wilms' tumor gene WT1 in solid tumors and its involvement in
tumor cell growth. Jpn J Cancer Res. 90:194–204. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Menssen HD, Bertelmann E, Bartelt S,
Schmidt RA, Pecher G, Schramm K and Thiel E: Wilms' tumor gene
(WT1) expression in lung cancer, colon cancer and glioblastoma cell
lines compared to freshly isolated tumor specimens. J Cancer Res
Clin Oncol. 126:226–232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakatsuka S, Oji Y, Horiuchi T, Kanda T,
Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M,
et al: Immunohistochemical detection of WT1 protein in a variety of
cancer cells. Mod Pathol. 19:804–814. 2006.PubMed/NCBI
|
|
33
|
Miyoshi Y, Ando A, Egawa C, Taguchi T,
Tamaki Y, Tamaki H, Sugiyama H and Noguchi S: High expression of
Wilms' tumor suppressor gene predicts poor prognosis in breast
cancer patients. Clin Cancer Res. 8:1167–1171. 2002.PubMed/NCBI
|
|
34
|
Mayo MW, Wang CY, Drouin SS, Madrid LV,
Marshall AF, Reed JC, Weissman BE and Baldwin AS: WT1 modulates
apoptosis by transcriptionally upregulating the bcl-2
proto-oncogene. EMBO J. 18:3990–4003. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Richard DJ, Schumacher V, Royer-Pokora B
and Roberts SG: Par4 is a coactivator for a splice isoform-specific
transcriptional activation domain in WT1. Genes Dev. 15:328–339.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai
Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, et al:
Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms
on the intrinsic apoptosis pathway. Oncogene. 25:4217–4229. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tatsumi N, Oji Y, Tsuji N, Tsuda A,
Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, et
al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing
agent for solid tumors. Int J Oncol. 32:701–711. 2008.PubMed/NCBI
|
|
38
|
Barbolina MV, Adley BP, Shea LD and Stack
MS: Wilms tumor gene protein 1 is associated with ovarian cancer
metastasis and modulates cell invasion. Cancer. 112:1632–1641.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Z, Yamanouchi K, Ohtao T, Matsumura S,
Seino M, Shridhar V, Takahashi T, Takahashi K and Kurachi H: High
levels of Wilms' tumor 1 (WT1) expression were associated with
aggressive clinical features in ovarian cancer. Anticancer Res.
34:2331–2340. 2014.PubMed/NCBI
|
|
40
|
Qi XW, Zhang F, Yang XH, Fan LJ, Zhang Y,
Liang Y, Ren L, Zhong L, Chen QQ, Zhang KY, et al: High Wilms'
tumor 1 mRNA expression correlates with basal-like and ERBB2
molecular subtypes and poor prognosis of breast cancer. Oncol Rep.
28:1231–1236. 2012.PubMed/NCBI
|
|
41
|
Zapata-Benavides P, Tuna M,
Lopez-Berestein G and Tari AM: Downregulation of Wilms' tumor 1
protein inhibits breast cancer proliferation. Biochem Biophys Res
Commun. 295:784–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tuna M, Chavez-Reyes A and Tari AM:
HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein
to stimulate S-phase proliferation and inhibit apoptosis in breast
cancer cells. Oncogene. 24:1648–1652. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu
C and Jiang J: Wilms' tumor 1 (WT1) expression and prognosis in
solid cancer patients: A systematic review and meta-analysis. Sci
Rep. 5:89242015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu C, Wu C, Xia Y, Zhong Z, Liu X, Xu J,
Cui F, Chen B, Røe OD, Li A and Chen Y: WT1 promotes cell
proliferation in non-small cell lung cancer cell lines through
up-regulating cyclin D1 and p-pRb in vitro and in vivo. PLoS One.
8:e688372013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu C, Wang S, Xu C, Tyler A, Li X,
Andersson C, Oji Y, Sugiyama H, Chen Y and Li A: WT1 enhances
proliferation and impedes apoptosis in KRAS mutant NSCLC via
targeting cMyc. Cell Physiol Biochem. 35:647–662. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu C, Wang Y, Xia Y, He S, Wang Z, Chen Y,
Wu C, Shu Y and Jiang J: Wilms' tumor 1 enhances
Cisplatin-resistance of advanced NSCLC. FEBS Lett. 588:4566–4572.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu C, Zhu W, Qian J, He S, Wu C, Chen Y
and Shu Y: WT1 promotes invasion of NSCLC via suppression of CDH1.
J Thorac Oncol. 8:1163–1169. 2013. View Article : Google Scholar : PubMed/NCBI
|
